Pharmaceutical Research

, Volume 13, Issue 1, pp 32–37 | Cite as

Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique

  • Bernhard G. Müller
  • Hans Leuenberger
  • Thomas Kissel
Article

Abstract

Purpose. The purpose of this study was to develop a new method to produce albumin particles in the sub-200-nanometer range with a narrow size distribution and in a controlled and reproducible manner.

Methods. A new emulsion crosslinking method was developed using ultrasound and static mixing as homogenization steps and a central composite design was used to evaluate the influence of different process parameters on particle size, polydispersity and yield.

Results. Response surface analysis allowed the location of the most important factors. Of all the factors investigated, only the albumin concentration and the aqueous phase volume showed a significant influence on response parameters. Albumin nanospheres with sizes below 200 nm in diameter and very narrow size distributions were obtained in high yields (>80%).

Conclusions. This study describes a new preparation method for albumin nanoparticles which are suitable for future drug targeting studies.

albumin nanospheres manufacturing glutaraldehyde cross-linking central composite design 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    P.K. Gupta and C.T. Hung. Albumin microspheres II: applications in drug delivery. J. Microencapsulation 6: 463–472 (1989).Google Scholar
  2. 2.
    L. Illum, S.S. Davis, C.G. Wilson, N. Thomas, M. Frier and J.G. Hardy. Blood clearance and organ deposition of intravenously administered colloidal particles: the effects of particle size, nature and shape. Int. J. Pharm. 12: 135 (1982).Google Scholar
  3. 3.
    E. Tomlinson, J.J. Burger. Monolithic albumin particles as drug carriers. In: L. Illum, J.G. McVie and E. Tomlinson (eds.), Polymers in Controlled Drug Delivery, Wright, Bristol, 1987, pp. 25–48.Google Scholar
  4. 4.
    B.G. Müller and T. Kissel. Camouflage nanospheres: a new approach to bypassing phagocytic blood clearance by surface modified particulate carriers. Pharm. Pharmacol. Lett. 3: 67–70 (1993).Google Scholar
  5. 5.
    R. Arshady. Albumin microspheres and microcapsules: methodology of manufacturing techniques. J. Controlled Release 14: 111–131 (1990).Google Scholar
  6. 6.
    M. Roser and T. Kissel. Surface-modified biodegradable albumin nano-and microspheres: I. Preparation and characterization. Eur. J. Biopharm. 39: 8–12 (1993).Google Scholar
  7. 7.
    N. Ostrowski. Particle characterization by photon correlation spectroscopy. In P.J. Lloyd (ed.), Particle Size Analysis 1988. John Wiley, Chichester, 1988.Google Scholar
  8. 8.
    E. Tomlinson and J.J. Burger. Incorporation of water-soluble drugs in albumin microspheres. In K.J. Widder and R. Green (eds.), Methods in Enzymology, Academic Press, Orlando, 1985, pp. 27–42Google Scholar
  9. 9.
    H. Leuenberger. Mathematische Versuchsplanung und Optimierungsstrategien. In H. Sucker, P. Fuchs and P. Speiser (eds.), Pharmazeutische Technologie, Georg Thieme Verlag, Stuttgart, 1991.Google Scholar
  10. 10.
    Statgraphics (Release 5.22), STSC Inc., Rockville, USA.Google Scholar
  11. 11.
    G.E.P. Box, N.R. Draper. Empirical Model-Building and Response Surfaces, Wiley, New York, 1987.Google Scholar
  12. 12.
    G. Derringer and R. Suich. Simultaneous Optimization of Several Response Variables. J. Quality Technology 12: 214–219 (1980).Google Scholar
  13. 13.
    J.J. Torrado, L. Illum and S.S. Davis. Particle size and size distribution of albumin microspheres produced by heat and chemical stabilization. Int. J. Pharm. 51: 85–93 (1989).Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Bernhard G. Müller
    • 1
    • 2
  • Hans Leuenberger
    • 2
  • Thomas Kissel
    • 3
  1. 1.Pharma Development, Drug Delivery Systems Dept.Sandoz Pharma LTDBaselSwitzerland
  2. 2.School of PharmacyUniversity of BaselBaselSwitzerland
  3. 3.Department of Pharmaceutics and BiopharmacyPhilipps-UniversityMarburgF.R. Germany

Personalised recommendations